Optimization of the clofazimine structure leads to a highly water-soluble C3-aminopyridinyl riminophenazine endowed with improved anti-Wnt and anti-cancer activity in vitro and in vivo.

European Journal of Medicinal Chemistry
Alexey KovalVladimir L Katanaev

Abstract

Triple-negative breast cancer (TNBC) is a cancer subtype critically dependent upon excessive activation of Wnt pathway. The anti-mycobacterial drug clofazimine is an efficient inhibitor of canonical Wnt signaling in TNBC, reducing tumor cell proliferation in vitro and in animal models. These properties make clofazimine a candidate to become first targeted therapy against TNBC. In this work, we optimized the clofazimine structure to enhance its water solubility and potency as a Wnt inhibitor. After extensive structure-activity relationships investigations, the riminophenazine 5-(4-(chlorophenyl)-3-((2-(piperazin-1-yl)ethyl)imino)-N-(pyridin-3-yl)-3,5-dihydrophenazin-2-amine (MU17) was identified as the new lead compound for the riminophenazine-based targeted therapy against TNBC and Wnt-dependent cancers. Compared to clofazimine, the water-soluble MU17 displayed a 7-fold improved potency against Wnt signaling in TNBC cells resulting in on-target suppression of tumor growth in a patient-derived mouse model of TNBC. Moreover, allowing the administration of reduced yet effective dosages, MU17 displayed no adverse effects, most notably no clofazimine-related skin coloration.

References

Jan 24, 2004·Cancer Biology & Therapy·Louise R Howe, Anthony M C Brown
Nov 11, 2008·Journal of Chemical Information and Modeling·Timothy J CheeserightJeremy G Vinter
Jan 9, 2010·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Elena López-KnowlesSandra A O'Toole
Feb 13, 2010·Journal of Cheminformatics·Andreas JahnAndreas Zell
Dec 7, 2010·The Biochemical Journal·Alexey Koval, Vladimir L Katanaev
Feb 15, 2011·Biochemistry. Biokhimii︠a︡·V L Katanaev
Nov 28, 2012·International Journal of Trichology·Mariam PhilipPuthenveedu Salahudeen Simi
Apr 16, 2013·Trends in Pharmacological Sciences·Natalia Novac
Dec 4, 2014·Bioorganic & Medicinal Chemistry·Michele TonelliRoberta Loddo
Dec 17, 2014·Bioorganic & Medicinal Chemistry·Anna BarteselliAnna Sparatore
Jan 1, 2014·Molecular and Cellular Therapies·Artem BlagodatskiVladimir L Katanaev
Aug 12, 2015·The American Journal of Tropical Medicine and Hygiene·Liwang CuiPhilip J Rosenthal
Jul 20, 2016·Cancers·Kamal AhmedVladimir L Katanaev
Jan 25, 2017·Journal of Medicinal Chemistry·Andrea AstolfiVioletta Cecchetti
Jun 4, 2017·The AAPS Journal·Tiejun ChengYanli Wang
May 11, 2018·Scientific Reports·Alexey Koval, Vladimir L Katanaev
Oct 13, 2018·Nature Reviews. Drug Discovery·Sudeep PushpakomMunir Pirmohamed
Oct 29, 2019·ChemMedChem·Ivan BassaniniAnna Sparatore
Dec 29, 2020·Frontiers in Oncology·Jiabin XuVladimir L Katanaev
Jul 17, 2019·Frontiers in Big Data·Mohan S RaoTerry R Van Vleet

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.